Loading...
| A14514 | Pages: 220 | Nov 2021 | 519 Views | | |
| Author(s) : Shilpi Chowdhury , Onkar Sumant | Tables: 118 | Charts: 55 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Hepatitis Therapeutics Market
Request Now !The global hepatitis therapeutics market size was valued at $14,480 Million in 2020 and is projected to reach $19,716 Million by 2030 registering a CAGR of 3.1% from 2021 to 2030. Hepatitis is the inflammation of liver caused because of viral disease. Hepatitis is caused due to different infections known as infection A, infection B, infection C, infection D, infection E and infection G. The disease prompts irritation of liver tissues, which can trigger liver cirrhosis and malignant growth. The disease decreases liver capacity and harm to other body capacities. Hepatitis can be acute and chronic both. Among every one of the kinds, hepatitis B and C are the most hazardous and hard to treat.
The development of the hepatitis therapeutics market is driven by ascend in commonness of different hepatitis, expanding research and development work, clinical preliminaries of hepatitis drugs, expansion in number of item endorsements and product launches and development of novel hepatitis drugs in the treatment of different kinds of hepatitis. Increasing research coordinated efforts for the development of powerful medications in pipeline drives the market growth significantly. Besides, associations and joint effort in significant organizations ascend in persistent mindfulness in regards to hepatitis therapeutics treatment, and presentation of low-estimated hepatitis therapeutics is different variables that support the development of the market.
Get more information on this report : Request Sample Pages
However, significant expense of hepatitis drugs is relied upon to limit the development of the hepatitis therapeutics market. On the other hand, growing opportunities in emerging countries and sectors are anticipated to offer lucrative growth opportunities in the near future.
The outbreak of COVID-19 has disrupted workflows in the healthcare sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare.
There has also been a moderate effect on various healthcare services, including the hepatitis therapeutics market. The COVID-19 pandemic is an unpredicted worldwide general wellbeing challenge and is expected to adversely affect the hepatitis therapeutics market for the advancement of hepatitis drugs treatment to treat a wide range of hepatitis(s). During the COVID-19 pandemic from one side of the planet to the other, patients with hepatitis B have confronted various new difficulties in getting to clinical consideration and treatment because of deferred arrangements and de-prioritization of routine hepatitis or essential consideration administrations. Larger part of patients needed to change in accordance with telemedicine process, yet they additionally experienced trouble getting antiviral tops off and interruptions in mail-request conveyance of the medications. Some patients experienced issues when diagnosed with COVID-19 and with liver sickness at the same time.
Concerns were identified with the security and viability of COVID-19 antibodies for individuals living with hepatitis B and liver illness. In 2020, the COVID-19 pandemic disturbed the whole HCV benefits worldwide, with 25% fewer patients being started on treatment than in 2019. Hence, the overall impact of COVID-19 on hepatitis therapeutics market is positive, which will further drive the market growth.
The global hepatitis therapeutics market is segmented on the basis of disease type, drug class, distribution channel and region. On the basis of disease type, the market is further classified into hepatitis B, hepatitis C, and others (hepatitis A, D, E and G). By drug class, it is divided into oral antivirals, and immune modulators. Based on distribution channel, it is subdivided in to hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Get more information on this report : Request Sample Pages
By disease type, the hepatitis C segment accounted for the largest share of the hepatitis therapeutics market in 2020. The large share of this segment can be attributed to the increasing prevalence of hepatitis C and rising product approvals by regulatory authorities.
Further, drug stores & retail pharmacies segment is anticipated to depict largest growth during the forecast period, due to increasing drug availability of both branded and generics. In addition, online providers are expected to witness fastest growth owing to the lucrative discount offers provided by the online providers, which is expected to attract more customers to opt for online provider’s services.
Get more information on this report : Request Sample Pages
North America is projected to account for a major share of the global hepatitis therapeutics market during the forecast period. The market in the region is anticipated to witness growth in the future, owing to large patient population of hepatitis patients, huge availability of both branded and generic medications. And rising number of product approvals are propelling market growth in North America.
The key market players profiled in the report include Abbvie Inc., Bristol Myers & Squibb, Cipla Inc., Gilead Sciences Inc., GlaxoSmithKline Plc, Hoffmann-La Roche Ltd., Lupin Ltd., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., and Zydus Cadila.
Get more information on this report : Request Sample Pages
Key Benefits for Stakeholders
Key Market Segments
CHAPTER 1:INTRODUCTION
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increasing Product Approvals and Launches
3.5.1.2.Rising Collaborations between Major Players in the Market
3.5.1.3.Robust Presence of Pipeline Drugs
3.5.2.Restraint
3.5.2.1.High Cost of Hepatitis Drugs
3.5.3.Opportunities
3.5.3.1.Growth Opportunities in Emerging Markets
3.5.4.Impact analysis
3.6.Covid-19 Impact analysis on hepatitis therapeutics market
CHAPTER 4:HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Hepatitis B
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Hepatitis C
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Others (A, D, E and G)
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
CHAPTER 5:HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS
5.1.Overview
5.1.1.Market size and forecast
5.2.Oral Antivirals
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Immune Modulators
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
CHAPTER 6:HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospital Pharmacies
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Drug Stores & Retail Pharmacies
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Online Providers
6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country
CHAPTER 7:HEPATITIS THERAPEUTICS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country
7.2.2.1.U.S.
7.2.2.1.1.U.S. hepatitis therapeutics market, by Disease Type
7.2.2.1.2.U.S. hepatitis therapeutics market, by Drug Class
7.2.2.1.3.U.S. hepatitis therapeutics market, by Distribution Channel
7.2.2.2.Canada
7.2.2.2.1.Canada hepatitis therapeutics market, by Disease Type
7.2.2.2.2.Canada hepatitis therapeutics market, by Drug Class
7.2.2.2.3.Canada hepatitis therapeutics market, by Distribution Channel
7.2.2.3.Mexico
7.2.2.3.1.Mexico hepatitis therapeutics market, by Disease Type
7.2.2.3.2.Mexico hepatitis therapeutics market, by Drug Class
7.2.2.3.3.Mexico hepatitis therapeutics market, by Distribution Channel
7.2.3.North America market size and forecast, by Disease Type
7.2.4.North America market size and forecast, by Drug Class
7.2.5.North America market size and forecast, by Distribution Channel
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country129
7.3.2.1.Germany
7.3.2.1.1.Germany hepatitis therapeutics market, by Disease Type
7.3.2.1.2.Germany hepatitis therapeutics market, by Drug Class
7.3.2.1.3.Germany hepatitis therapeutics market, by Distribution Channel
7.3.2.2.France
7.3.2.2.1.France hepatitis therapeutics market, by Disease Type
7.3.2.2.2.France hepatitis therapeutics market, by Drug Class
7.3.2.2.3.France hepatitis therapeutics market, by Distribution Channel
7.3.2.3.UK
7.3.2.3.1.UK hepatitis therapeutics market, by Disease Type
7.3.2.3.2.UK hepatitis therapeutics market, by Drug Class
7.3.2.3.3.UK hepatitis therapeutics market, by Distribution Channel
7.3.2.4.Italy
7.3.2.4.1.Italy hepatitis therapeutics market, by Disease Type
7.3.2.4.2.Italy hepatitis therapeutics market, by Drug Class
7.3.2.4.3.Italy hepatitis therapeutics market, by Distribution Channel
7.3.2.5.Spain
7.3.2.5.1.Spain hepatitis therapeutics market, by Disease Type
7.3.2.5.2.Spain hepatitis therapeutics market, by Drug Class
7.3.2.5.3.Spain hepatitis therapeutics market, by Distribution Channel
7.3.2.6.Rest of Europe
7.3.2.6.1.Rest of Europe hepatitis therapeutics market, by Disease Type
7.3.2.6.2.Rest of Europe hepatitis therapeutics market,
by Drug Class
7.3.2.6.3.Rest of Europe hepatitis therapeutics market,
by Distribution Channel
7.3.3.Europe market size and forecast, by Disease Type
7.3.4.Europe market size and forecast, by Drug Class
7.3.5.Europe market size and forecast, by Distribution Channel
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country
7.4.2.1.Japan
7.4.2.1.1.Japan hepatitis therapeutics market, by Disease Type
7.4.2.1.2.Japan hepatitis therapeutics market, by Drug Class
7.4.2.1.3.Japan hepatitis therapeutics market, by Distribution Channel
7.4.2.2.China
7.4.2.2.1.China hepatitis therapeutics market, by Disease Type
7.4.2.2.2.China hepatitis therapeutics market, by Drug Class
7.4.2.2.3.China hepatitis therapeutics market, by Distribution Channel
7.4.2.3.Australia161
7.4.2.3.1.Australia hepatitis therapeutics market, by Disease Type
7.4.2.3.2.Australia hepatitis therapeutics market, by Drug Class
7.4.2.3.3.Australia hepatitis therapeutics market, by Distribution Channel
7.4.2.4.India
7.4.2.4.1.India hepatitis therapeutics market, by Disease Type
7.4.2.4.2.India hepatitis therapeutics market, by Drug Class
7.4.2.4.3.India hepatitis therapeutics market, by Distribution Channel
7.4.2.5.South Korea
7.4.2.5.1.South Korea hepatitis therapeutics market, by Disease Type
7.4.2.5.2.South Korea hepatitis therapeutics market, by Drug Class
7.4.2.5.3.South Korea hepatitis therapeutics market, by Distribution Channel
7.4.2.6.Rest of Asia-Pacific
7.4.2.6.1.Rest of Asia-Pacific hepatitis therapeutics market,
by Disease Type
7.4.2.6.2.Rest of Asia-Pacific hepatitis therapeutics market,
by Drug Class
7.4.2.6.3.Rest of Asia-Pacific hepatitis therapeutics market,
by Distribution Channel
7.4.3.Asia-Pacific market size and forecast, by Disease Type
7.4.4.Asia-Pacific market size and forecast, by Drug Class
7.4.5.Asia-Pacific market size and forecast, by Distribution Channel
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country177
7.5.2.1.Latin America
7.5.2.1.1.Latin America hepatitis therapeutics market, by Disease Type
7.5.2.1.2.Latin America hepatitis therapeutics market, by Drug Class179
7.5.2.1.3.Latin America hepatitis therapeutics market, by Distribution Channel
7.5.2.2.Middle East and Africa
7.5.2.2.1.Middle East and Africa hepatitis therapeutics market, by Disease Type
7.5.2.2.2.Middle East and Africa hepatitis therapeutics market, by Drug Class182
7.5.2.2.3.Middle East and Africa hepatitis therapeutics market, by Distribution Channel
7.5.3.LAMEA market size and forecast, by Disease Type
7.5.4.LAMEA market size and forecast, by Drug Class
7.5.5.LAMEA market size and forecast, by Distribution Channel
CHAPTER 8:COMPANY PROFILES
8.1.ABBVIE INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.BRISTOL MAYERS & SQUIBB
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.CIPLA INC.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.GILEAD SCIENCES INC.
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Key strategic moves and developments
8.5.GLAXOSIMITHKLINE PLC
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.HOFFMANN-LA ROCHE LTD.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.7.LUPIN LTD.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Key strategic moves and developments
8.8.MERCK & CO. INC.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.TEVA PHARMACEUTICAL INDUSTRIES LTD.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.1.Business performance
8.9.2.Key strategic moves and developments
8.10.ZYUDUS CADILA
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Product Portfolio
8.10.4.Business performance
8.10.5.Key strategic moves and developments
LIST OF TABLES
TABLE 01.HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 02.HEPATITIS B HEPATITIS THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03.HEPATITIS C HEPATITIS THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 04.OTHERS (A, D, E AND G) HEPATITIS THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05.HUMAN HEPATITIS THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 06.HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 07.HEPATITIS THERAPEUTICS MARKET FOR CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 08.HEPATITIS THERAPEUTICS MARKET FOR CANCER, BY TYPE, 2020–2030 ($MILLION)
TABLE 09.HEPATITIS THERAPEUTICS MARKET FOR IMMUNE MODULATORS, BY REGION, 2020-2030 ($MILLION)
TABLE 10.HEPATITIS THERAPEUTICS MARKET FOR INFLAMMATORY DISEASES, BY REGION, 2020-2030 ($MILLION)
TABLE 11.HEPATITIS THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020-2030 ($MILLION)
TABLE 12.HEPATITIS THERAPEUTICS MARKET FOR OTHER DRUG CLASSS, BY REGION, 2020-2030 ($MILLION)
TABLE 13.HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 14.HEPATITIS THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2020-2030 ($MILLION)
TABLE 15.HEPATITIS THERAPEUTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2020-2030 ($MILLION)
TABLE 16.HEPATITIS THERAPEUTICS MARKET FOR OTHER DISTRIBUTION CHANNEL, BY REGION, 2020-2030 ($MILLION)
TABLE 17.HEPATITIS THERAPEUTICS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 18.NORTH AMERICA HEPATITIS THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 19.U.S. HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 20.U.S. HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 21.U.S. HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 22.CANADA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 23.CANADA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 24.CANADA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 25.MEXICO HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 26.MEXICO HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 27.MEXICO HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 28.NORTH AMERICA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 29.NORTH AMERICA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 30.NORTH AMERICA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 31.EUROPE HEPATITIS THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 32.GERMANY HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 33.GERMANY HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 34.GERMANY HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 35.FRANCE HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION
TABLE 36.FRANCE HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 37.FRANCE HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 38.UK HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 39.UK HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 40.UK HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 41.ITALY HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 42.ITALY HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 43.ITALY HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 44.SPAIN HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 45.SPAIN HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 46.SPAIN HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 47.REST OF EUROPE HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 48.REST OF EUROPE HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 49.REST OF EUROPE HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 50.EUROPE HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 51.EUROPE HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 52.EUROPE HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 53.ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 54.JAPAN HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 55.JAPAN HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 56.JAPAN HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 57.CHINA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 58.CHINA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 59.CHINA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 60.AUSTRALIA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 61.AUSTRALIA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 62.AUSTRALIA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 63.INDIA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 64.INDIA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 65.INDIA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 66.SOUTH KOREA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 67.SOUTH KOREA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 68.SOUTH KOREA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 69.REST OF ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 70.REST OF ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 72.ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 73.ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 74.ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 75.LAMEA HEPATITIS THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 76.BRAZIL HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 77.BRAZIL HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 78.BRAZIL HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 79.SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 80.SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 81.SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 82.SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 83.SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 84.SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 85.REST OF LAMEA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 86.REST OF LAMEA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 87.REST OF LAMEA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 88.LAMEA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 89.LAMEA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 90.LAMEA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 91.ABBVIE: COMPANY SNAPSHOT
TABLE 92.ABBVIE: OPERATING SEGMENTS
TABLE 93.ABBVIE : PRODUCT PORTFOLIO
TABLE 94.BMS: COMPANY SNAPSHOT
TABLE 95.BMS: PRODUCT PORTFOLIO
TABLE 96.CIPLA: COMPANY SNAPSHOT
TABLE 97.CIPLA: OPERATING SEGMENTS
TABLE 98.CIPLA: PRODUCT PORTFOLIO
TABLE 99.GILEAD: COMPANY SNAPSHOT
TABLE 100.GILEAD: OPERATING SEGMENTS
TABLE 101.GILEAD: PRODUCT PORTFOLIO
TABLE 102.GSK: COMPANY SNAPSHOT
TABLE 103.GSK: OPERATING SEGMENTS
TABLE 104.GSK: PRODUCT PORTFOLIO
TABLE 105.ROCHE: COMPANY SNAPSHOT
TABLE 106.ROCHE: OPERATING SEGMENTS
TABLE 107.ROCHE: PRODUCT PORTFOLIO
TABLE 108.LUPIN: COMPANY SNAPSHOT
TABLE 109.LUPIN: OPERATING SEGMENTS
TABLE 110.LUPIN: PRODUCT PORTFOLIO
TABLE 111.MERCK: COMPANY SNAPSHOT
TABLE 112.MERCK: OPERATING SEGMENTS
TABLE 113.MERCK: PRODUCT PORTFOLIO
TABLE 114.TEVA: COMPANY SNAPSHOT
TABLE 115.TEVA: OPERATING SEGMENTS
TABLE 116.TEVA: PRODUCT PORTFOLIO
TABLE 117.ZYDUS: COMPANY SNAPSHOT
TABLE 118.ZYDUS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.HEPATITIS THERAPEUTICS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.HIGH INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF HEPATITIS B HEPATITIS THERAPEUTICS MARKET, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF HEPATITIS C HEPATITIS THERAPEUTICS MARKET, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF OTHERS (A, D, E AND G) HEPATITIS THERAPEUTICS MARKET, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF HUMAN HEPATITIS THERAPEUTICS MARKET, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF HEPATITIS THERAPEUTICS MARKET FOR CANCER, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF HEPATITIS THERAPEUTICS MARKET FOR IMMUNE MODULATORS,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF HEPATITIS THERAPEUTICS MARKET FOR INFLAMMATORY DISEASES,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 25.COMPARATIVE ANALYSIS OF HEPATITIS THERAPEUTICS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS OF HEPATITIS THERAPEUTICS MARKET FOR OTHER DRUG CLASSS,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 27.COMPARATIVE ANALYSIS OF HEPATITIS THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 28.COMPARATIVE ANALYSIS OF HEPATITIS THERAPEUTICS MARKET FOR RESEARCH INSTITUTES,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 29.COMPARATIVE ANALYSIS OF HEPATITIS THERAPEUTICS MARKET FOR OTHER DISTRIBUTION CHANNEL,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 30.ABBVIE: NET SALES, 2018–2020 ($MILLION)
FIGURE 31.ABBVIE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 32.BMS: NET SALES, 2018–2020 ($MILLION)
FIGURE 33.BMS: REVENUE SHARE, BY REGION 2020 (%)
FIGURE 34.CIPLA: NET SALES, 2018–2020 ($MILLION)
FIGURE 35.CIPLA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36.CIPLA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 37.GILEAD: NET SALES, 2018–2020 ($MILLION)
FIGURE 38.GILEAD: REVENUE SHARE, BY SEGMENT 2020 (%)
FIGURE 39.GILEAD: REVENUE SHARE, BY REGION 2020 (%)
FIGURE 40.GSK: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.GSK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 42.GSK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 43.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 44.ROCHE: REVENUE SHARE, BY SEGMENT 2020 (%)
FIGURE 45.ROCHE: REVENUE SHARE, BY REGION 2020 (%)
FIGURE 46.LUPIN : NET SALES, 2018–2020 ($MILLION)
FIGURE 47.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 48.MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 49.MERCK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 50.TEVA PHARMACEUTICALS: NET SALES, 2018–2020 ($MILLION)
FIGURE 51.TEVA PHARMACEUTICALS: REVENUE SHARE BY SEGMENT 2020 (%)
FIGURE 52.TEVA PHARMACEUTICALS: REVENUE SHARE, BY REGION 2020 (%)
FIGURE 53.ZYDUS: NET SALES, 2018-2020 (%)
FIGURE 54.ZYDUS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 55.ZYDUS: REVENUE SHARE BY REGION 2020 (%)
Hepatitis therapeutics market growth includes rise in number of hepatitis patient population across the globe, rise in public awareness toward hepatitis and treatment and prevention methods has primarily driven the market growth over the past few years. Moreover, introduction of low-priced hepatitis therapeutic drugs are a major contributing factor for revenue generation in this market. Moreover, the market is witnessing intensified competition among the market players owing to the rising collaborations between major players. There has been an increased focus on the hepatitis therapeutics because of increased R&D activities and clinical trials on the drug candidates. Further, surge in hepatitis awareness and popularity of novel hepatitis therapeutics are expected to drive the growth of the market. On the contrary with market drivers, there are some major restraining factors such as high cost of hepatitis treatment therapy that limits the growth of the market. Furthermore, increase in demand of hepatitis therapeutics in emerging markets such as India, China, and Brazil is anticipated offer lucrative opportunities to the hepatitis therapeutics market over the forecast period.
Furthermore, hepatitis therapeutics market is dominated by North America due to the strong presence of the pharmaceuticals and biotechnology companies in the U.S. and is followed by Europe. The large share of North America can be attributed to factors such as the rising prevalence of hepatitis and its variants, and surge in research collaborations for the development of robust drugs pipeline, which are propelling the market growth in North America.
A. The total market value of Hepatitis Therapeutics market is $14,479.64 million in 2020.
A. The forcast period for Hepatitis Therapeutics market is 2021 to 2030
A. The market value of Hepatitis Therapeutics market in 2021 is $19,715.74 million.
A. The base year is 2020 in Hepatitis Therapeutics market
A. Top companies such as Abbvie Inc., Bristol Mayers & Squibb, Cipla Inc., Gilead Sciences Inc., GlaxoSmithKline Plc, Hoffmann-La Roche Ltd., Lupin Ltd., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., and Zydus Cadila held a high market position in 2020.
A. Based on drugs class, the CRISPR segment accounted for the largest share of the Hepatitis Therapeutics market in 2020. The large share of this segment can be attributed to the increasing demnad of the oral antivirals medications, rising products approvals and launches for treatment of hepatitis.
A. The growth of the hepatitis therapeutics market is driven by rise in prevalence of various hepatitis, increasing research and development, clinical trials of hepatitis drugs, increase in number of product approvals and product launch and surge in adoption of novel hepatitis drugs in the treatment of various types of hepatitis. However, high cost of hepatitis drugs is expected to restrain the growth of the hepatitis therapeutics market.
A. North America is projected to account for a major share of the global Hepatitis Therapeutics market during the forecast period. The market in the region is anticipated to grow in the future, owing to rising R&D activities in the U.S., large patient population of hepatitis patients, huge availability of both branded and generic medications. And rising number of product approvals are propelling market growth in North America.
A. Hepatitis Therapeutics refers to the medication that are used for the treatmet of hepatitis and its all variants. Oral antivirals and immune modulators are the two medications used to treat hepatitis.
A. The hepatitis therapeutics medications are used to treat all type of hepatitis that includes Hepatitis A, B, C, D and E.
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
